Xaracoll FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 17, 2020.
FDA Approved: Yes (First approved August 28, 2020)
Brand name: Xaracoll
Generic name: bupivacaine hydrochloride
Dosage form: Implant
Company: Innocoll Holdings Limited
Treatment for: Postsurgical Pain Relief Following Open Inguinal Hernia
Xaracoll (bupivacaine hydrochloride) is a fully bioresorbable collagen implant containing the local anesthetic bupivacaine indicated for acute postsurgical pain relief for up to 24 hours in adults following open inguinal hernia repair.
- Xaracoll is placed at the surgical site and releases bupivacaine hydrochloride through diffusion (immediately and over time) from the porous collagen implant, which dissolves over time.
Development timeline for Xaracoll
| Date | Article |
|---|---|
| Aug 31, 2020 | Approval FDA Approves Xaracoll (bupivacaine hydrochloride) Implant for Acute Postsurgical Pain Relief Following Open Inguinal Hernia Repair |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
